ClinicalTrials.gg
Not yet recruitingNCT07546994BARRIERUpdated Apr 23, 2026

Biofilm-induced Antimicrobial Resistance RIsk ERadication in Critical Care Central Venous Catheters

An observational study in Catheter-Related Infections, Biofilms and Infection Prevention, sponsored by Centre Hospitalier Universitaire de Nīmes. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Catheter-Related Infections with a site in France — 4 open to participants now, 4 under way, none of them phase 3. Catheter-Related Infections · France.

Started
2026
with 3 others
Observational
6 of 16
2 open now
Registered
16th of 16
by date
Lead sponsor
2 of 16
Centre Hospitalier Universitaire de Nīmes

Among the 16 studies in Catheter-Related Infections with a site in France, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 16th registered.

Catheter-Related Infections

113 studies on the registry are indexed under Catheter-Related Infections; 19 are open to participants now.

Browse Catheter-Related Infections studies →

Open to participants now

4 of the 16 studies in Catheter-Related Infections with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 10 Catheter-Related Infections studies recruiting now, 9 (90%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Catheter-Related Infections with a site in France, or all of them as a file.
02

Study summary

Central venous catheter (CVC) infections are a frequent and serious nosocomial complication in critical care, leading to increased morbidity, mortality, and costs. The pathophysiology of these infections relies on the formation of a biofilm, an organized microbial structure that confers exceptional tolerance to anti-infectives and the immune system. However, data concerning the characteristics of the in vivo biofilm (kinetics, composition, endo- vs. extraluminal organization) on central venous catheters in intensive care patients are very limited, hindering the development of effective and targeted prevention strategies.

The main aim of this study is to quantify the density and describe the spatial distribution (extra- and intraluminal compartments) of the biofilm on infected or colonized central venous catheters, prospectively collected from patients in the critical care units.

03

Conditions studied

  • Catheter-Related Infections
  • Biofilms
  • Infection Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All central venous catheters (conventional, dialysis catheters, or PICC lines) that test positive for microorganisms.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Central venous catheters (conventional central venous lines, dialysis catheters, PICC lines) showing positive microbiological culture taken from adult patients in the critical care units (intensive care units, post-operative intensive care units and post-resuscitation intensive care units)
  • Patient consent is free, informed, and non-opposition, provided after delivery of an information letter and oral explanation.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with infected central venous catheters

    Other: Microbial analysis of catheter biofilm

Interventions

  • OtherMicrobial analysis of catheter biofilm

    Identification and sampling of the catheter, standard microbiological analysis, inclusion and transfer (INSERM platform), biofilm analysis, and collection of associated data (clinical, biological and related to the catheter).

06

What researchers measure

Primary outcomes

  1. Concentration (density) of viable bacterial biofilm

    Measured in Colony Forming Units per millilitre (CFU/mL) for each compartment of the central venous catheter (internal and external lumen of the catheter)

    Time frame: Baseline

Secondary outcomes

  1. Provide a descriptive analysis of the population of colonized or infected central venous catheters, including clinical, biological, and microbiological data.

    * Causative microorganism (categorical outcome) * Catheter-related data (binary, numerical or categorical outcomes): catheter type, duration of catheterization (in days), time between admission and catheter placement (in days), insertion site, catheter rank * Type of infection (categorical outcome) : colonization, local infection, catheter-related sepsis, or catheter-related bacteremia * Associated conditions (binary or categorical outcomes): immunosuppression, diagnostic category, patient intubated or previously intubated (with overlap with the catheter being analyzed), patient on dialysis or previously on dialysis (with overlap with the catheter being analyzed), antibiotic therapy during the lifespan of the catheter being analyzed, parenteral nutrition during the lifespan of the catheter being analyzed.

    Time frame: Baseline

  2. Evaluate correlation between biofilm density and the following factors: microbiological, catheter-related, clinical, and patient-related.

    See previous description of the outcomes

    Time frame: Baseline

  3. Evaluate correlation between the preferred location of biofilm and the following factors: microbiological, catheter-related, clinical, and patient-related.

    See previous description of the outcomes

    Time frame: Baseline

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Apr 23, 2026
StartEst.
Apr 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07546994
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Apr 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Apr 23, 2026

Study contacts

Nicolas Boulet
Contact
nicolas.boulet@chu-nimes.fr
+334 66 68 33 31
Nicolas Boulet
principal investigator · Centre Hospitalier Universitaire de Nīmes

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion